LFCR Stock Forecast & Price Target

Lifecore Biomedical is projected to experience significant improvements in its financial performance, with EBITDA expected to increase from $20.3 million (16.8% margin) in FY26 to $27.3 million (19.1% margin) in FY27. Furthermore, the company is anticipated to achieve positive free cash flow, with projections of $5.1 million in FY26 and $6.0 million in FY27, reflecting a strengthening cash generation capability. This positive trajectory in key financial metrics indicates a robust operational performance and a favorable outlook for the company's growth.

Lifecore Biomedical Inc is facing a negative outlook due to its projected lack of meaningful revenue growth until calendar year 2027, which raises concerns about its future financial performance. The company’s high leverage ratio, which is expected to decrease only gradually, further exacerbates its risk profile when compared to peers. Additionally, although Lifecore anticipates a 10% market growth in the fill/finish sector, expectations suggest that actual growth may be lower, primarily due to the competitive landscape involving small molecule injectables.